We are live on ! Find out more
BPMC

Blueprint Medicines
BPMC

Delisted

BPMC was delisted on the 17th of July, 2025.

Back to rankings

219 hedge funds and large institutions have $3.78B invested in Blueprint Medicines in 2019 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 87 increasing their positions, 56 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

209% more call options, than puts

Call options by funds: $90.8M | Put options by funds: $29.4M

55% more repeat investments, than reductions

Existing positions increased: 87 | Existing positions reduced: 56

3.21% more ownership

Funds ownership: 101.52% → 104.73% (+3.2%)

0% more funds holding in top 10

Funds holding in top 10: 8 → 8 (0)

0% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 29

0% less funds holding

Funds holding: 220 → 219 (-1)

19% less capital invested

Capital invested by funds: $4.68B → $3.78B (-$898M)

Holders
219
Holders Change
-1
Holders Change %
-0.45%
% of All Funds
4.8%
Holding in Top 10
8
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.18%
New
29
Increased
87
Reduced
56
Closed
29
Calls
$90.8M
Puts
$29.4M
Net Calls
+$61.4M
Net Calls Change
+$37.8M

Top Buyers

Rank Fund Capital Flow
1
CCM
Cadian Capital Management
New York
+$77.4M
2
Viking Global Investors
Viking Global Investors
Connecticut
+$21.7M
3
Westfield Capital Management
Westfield Capital Management
Massachusetts
+$20.3M
4
HM
HealthCor Management
New York
+$19.6M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$18.2M

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$28.5M
2
Invesco
Invesco
Georgia
-$24.3M
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$21.1M
4
AG
Artal Group
Luxembourg
-$13M
5
Federated Hermes
Federated Hermes
Pennsylvania
-$12.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
PAMU
26
Pictet Asset Management (UK)
United Kingdom
$38.6M +$5.58M +64,532 +14%
CAM
27
Cormorant Asset Management
Massachusetts
$36.2M +$12.4M +143,000 +41%
EAM
28
Eventide Asset Management
Massachusetts
$33.9M – – –
Loomis, Sayles & Company
29
Loomis, Sayles & Company
Massachusetts
$32.3M +$5.53M +64,012 +17%
BI
30
BVF Inc
California
$32.1M – – –
American Century Companies
31
American Century Companies
Missouri
$29.7M +$343K +3,964 +1%
DM
32
Deerfield Management
New York
$27.7M -$1.21M -14,054 -4%
Goldman Sachs
33
Goldman Sachs
New York
$26.9M +$1.16M +13,384 +4%
Brown Advisory
34
Brown Advisory
Maryland
$26.4M +$7.35M +85,048 +31%
VOYA Investment Management
35
VOYA Investment Management
Georgia
$25.5M +$8.54M +98,836 +40%
RSCM
36
Rock Springs Capital Management
Maryland
$24.5M +$2.25M +26,000 +8%
GTC
37
Ghost Tree Capital
New York
$23.9M -$4.32M -50,000 -13%
Charles Schwab
38
Charles Schwab
California
$22.3M +$1.57M +18,186 +6%
Deutsche Bank
39
Deutsche Bank
Germany
$22.2M -$759K -8,782 -3%
N
40
Nuveen
North Carolina
$16.8M +$413K +4,778 +2%
Bank of New York Mellon
41
Bank of New York Mellon
New York
$15.3M -$491K -5,676 -3%
Alkeon Capital Management
42
Alkeon Capital Management
New York
$13.8M +$5.4M +62,500 +50%
EVM
43
Eaton Vance Management
Massachusetts
$12.8M +$7.08M +81,894 +89%
NHAS
44
Novo Holdings A/S
Denmark
$12.5M +$3.26M +37,691 +28%
UBS AM
45
UBS AM
Illinois
$9.99M +$331K +3,834 +3%
DCM
46
DAFNA Capital Management
California
$9.05M – – –
JP Morgan Chase
47
JP Morgan Chase
New York
$8.93M +$782K +9,041 +8%
Two Sigma Investments
48
Two Sigma Investments
New York
$8.7M -$8.48M -98,156 -45%
Macquarie Group
49
Macquarie Group
Australia
$8.64M +$10.2M +117,558 New
Two Sigma Advisers
50
Two Sigma Advisers
New York
$8.6M +$251K +2,900 +3%
1
2
3 4 5

BPMC Hedge Fund Activity: Q3 2019 in Review

219 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q3 2019, worth a combined $3.78B — down 19% from $4.68B a quarter earlier.

Fund positioning in BPMC was balanced in Q3 2019: 29 funds opened new positions, 29 closed out, 87 added to existing stakes and 56 trimmed.

The largest buyer was Cadian Capital Management, adding an estimated $77.4M. The largest seller was Perceptive Advisors, cutting an estimated $28.5M.

  • 219 institutional investors held Blueprint Medicines (BPMC) as of Q3 2019, down from 220 in Q2 2019.
  • Funds reported $3.78B of Blueprint Medicines stock for Q3 2019, down 19% quarter-over-quarter.
  • 29 funds opened new Blueprint Medicines positions in Q3 2019 and 29 closed out, a net change of 0 holders.
  • The largest Blueprint Medicines buyer in Q3 2019 was Cadian Capital Management, an estimated $77.4M added.
  • The largest Blueprint Medicines seller in Q3 2019 was Perceptive Advisors, an estimated $28.5M sold.

Based on aggregated 13F filings for Q3 2019.